Why Some Biotech Startups Are Skipping AI in Drug Discovery

While artificial intelligence has become a buzzword in biotech, not every startup is convinced it belongs in drug discovery. According to a STAT+ report, a growing number of biotech companies are deliberately avoiding AI for early-stage drug development, arguing that the technology’s current limitations—such as data scarcity and biological complexity—make it less effective than traditional methods. Instead, these startups are focusing AI efforts on other areas like clinical trial optimization, manufacturing, and patient recruitment, where data is more structured and outcomes are more predictable. The report highlights that while AI has shown promise in identifying drug candidates, the high failure rates in later-stage trials suggest that the initial hype may not translate into real-world success. By pivoting away from discovery, these companies aim to reduce risk and allocate resources more efficiently. This strategic divergence underscores a broader debate in the industry about where AI can deliver the most value, and it signals that the technology’s role in biotech is still evolving. For investors and researchers, the takeaway is clear: AI’s greatest impact may not be in finding new drugs, but in making the entire development process faster and cheaper.